

DAKTARIN CREAM

Miconazole Nitrate

NAME OF THE MEDICINAL PRODUCT

DAKTARIN Cream
Miconazole nitrate 20 mg/g topical cream.

QUALITATIVE AND QUANTITATIVE COMPOSITION

DAKTARIN Cream: Each gram contains 20 mg of the active substance miconazole nitrate.

For excipients, see List of Excipients.

PHARMACEUTICAL FORM

DAKTARIN Cream: White homogeneous cream for topical use.

CLINICAL PARTICULARS

Therapeutic Indications

DAKTARIN Cream

Skin infections due to dermatophytes or yeasts, and other fungi such as: *Tinea capitis, corporis, manuum, barbae, cruris, pedis* (athlete's foot). Since DAKTARIN has an antibacterial effect on gram-positive bacteria, it may be used in mycoses secondarily infected with such bacteria (e.g. in napkin dermatitis).

Posology And Method Of Administration

DAKTARIN Cream

Apply some cream to the lesions twice daily. Rub the cream into the skin with your finger until it has fully penetrated. If the powder is used with the cream, a once daily application of both formulations is recommended.

The duration of therapy varies from 2 to 6 weeks depending on the localization and the severity of the lesion.

Treatment should be continued at least one week after disappearance of all signs and symptoms.

Contraindications

DAKTARIN Cream is contraindicated in individuals with a known hypersensitivity to miconazole or another ingredient of the formulation.

Special Warnings and Special Precautions for Use

If a reaction suggesting sensitivity or irritation should occur, the treatment should be discontinued.

DAKTARIN Cream must not come into contact with the eyes.

Interactions with Other Medicinal Products and Other Forms of Interaction

Miconazole administered systemically is known to inhibit CYP3A4/2C9. Due to the limited systemic availability after topical application (see Section 5.2 Pharmacokinetic properties), clinically relevant interactions occur very rarely. In patients on oral anticoagulants, such as warfarin, caution should be exercised and the anticoagulant effect should be monitored. The effects and side effects of some other drugs (e.g. oral hypoglycaemics and phenytoin), when co-administered with miconazole, can be increased and caution should be exercised.

Pregnancy and Lactation

Pregnancy

DAKTARIN Cream applied topically are minimally absorbed into the systemic circulation (bioavailability < 1%). Although there is no evidence that miconazole is embryotoxic or teratogenic in animals, potential hazards of prescribing DAKTARIN Cream, Powder, Lotion, or Tincture during pregnancy should always be weighed against the expected therapeutic benefits.

Lactation

Topically applied miconazole is minimally absorbed into the systemic circulation, and it is not known whether miconazole is excreted in human breast milk. Caution should be exercised when using topically applied miconazole products during lactation. (See Section 4.5 Interactions with other medicinal products and other forms of interaction.)

Effects on Ability to Drive and Use Machines

Not applicable.

Undesirable Effects

Clinical trial data

Adverse drug reactions reported among 834 patients who received miconazole 2% cream and/or placebo cream base in 21 double-blind clinical trials are presented in Table 1 below. Included in the table are all adverse events considered to be related to study drug. A dash indicates that the adverse reaction was not reported by patients in the specified treatment group.

Table 1: Adverse drug reactions reported by patients in either treatment group in 21 double-blind clinical trials of miconazole 2% cream versus placebo.

System Organ Class Adverse drug reaction	Miconazole 2% Cream (n=426), %	Placebo Cream Base (n=408), %
Overall adverse drug reactions	1.9	1.2
Skin and subcutaneous tissue disorders		
Skin burning sensation	0.2	0.7
Skin inflammation	0.2	--
Skin hypopigmentation	0.2	--
General disorders and administration site conditions		
Application site irritation	0.7	0.5
Application site burning	0.2	0.2
Application site pruritus	0.2	--
Application site reaction NOS	0.2	--
Application site warmth	0.2	--

Note: Individual patients may have reported more than a single event.

Postmarketing data

Adverse drug reactions from spontaneous reports during the worldwide post-marketing experience with DAKTARIN that meet threshold criteria are included in Table 2. The adverse drug reactions are ranked by frequency, using the following convention:

Very common	≥1/10
Common	≥1/100 and < 1/10
Uncommon	≥1/1,000 and < 1/100
Rare	≥1/10,000 and < 1/1,000
Very rare	< 1/10,000, including isolated reports

The frequencies provided below reflect reporting rates for adverse drug reactions from spontaneous reports, and do not represent more precise estimates of incidence that might be obtained in clinical or epidemiological studies.

Table 2: Postmarketing reports of adverse drug reactions

Immune system disorders Very rare	anaphylactic reaction, hypersensitivity, angioneurotic edema
Skin and subcutaneous tissue disorders Very rare	urticaria, contact dermatitis, rash, erythema, pruritus, skin burning sensation
General disorders and administration site conditions Very rare	application site reactions, including application site irritation

Overdose

Overdose

Symptoms

Topical use: Excessive use can result in skin irritation, which usually disappears after discontinuation of therapy.

Treatment

Accidental ingestion: DAKTARIN Cream is intended for topical use, not for oral use. Should accidental oral ingestion of large quantities of these products occur, an appropriate method of gastric emptying may be used if considered necessary.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic Properties

Pharmaco-therapeutic classification: (Antifungals for dermatological/topical use; imidazole derivative.)

ATC code: D01A C02

Miconazole combines an antifungal activity against the common dermatophytes, yeasts and various other fungi with an antibacterial activity against certain gram-positive bacilli and cocci.

Miconazole inhibits the biosynthesis of ergosterol in fungi and changes the composition of other lipid components in the membrane, resulting in fungal cell necrosis.

Miconazole has also been proven to be effective in secondarily infected mycoses.

Usually, miconazole acts very rapidly on pruritus, which frequently accompanies dermatophyte and yeast infections. This symptomatic improvement is seen before the first signs of healing are observed.

Pharmacokinetic Properties

Absorption: Miconazole remains in the skin after topical application for up to 4 days. Systemic absorption of miconazole is limited, with a bioavailability of less than 1% following topical application of miconazole. Plasma concentrations of miconazole and/or its metabolites were measurable 24 and 48 hours after application.

Systemic absorption has also been demonstrated after repeated application of miconazole to infants with diaper dermatitis. Plasma levels of miconazole were undetectable or low in all infants.

Distribution: Absorbed miconazole is bound to plasma proteins (88.2%) and red blood cells (10.6%).

Metabolism and Excretion: The small amount of miconazole that is absorbed is eliminated predominantly in feces as both unchanged drug and metabolites over a four-day post-administration period. Smaller amounts of unchanged drug and metabolites also appear in urine.

Preclinical Safety Data

Preclinical data reveal no special hazard for humans based on conventional studies of local irritation, single and repeated dose toxicity, genotoxicity, and toxicity to reproduction.

PHARMACEUTICAL PARTICULARS

List of Excipients

DAKTARIN Cream: The cream formulation consists of PEG-6 (and) PEG-32 (and) glycol stearate, oleoyl macroglycerides, liquid paraffin, benzoic acid, butylated hydroxyanisole, purified water.

Incompatibilities

None known

Shelf Life

Observe expiry date on the outer pack.

Special Precautions for Storage

DAKTARIN Cream: Store at 25°C or below.

Nature and Contents of Container

Daktarin cream is supplied in tubes of 15 g

Instructions for Use and Handling (and Disposal)

DAKTARIN Cream: To open the tube, unscrew the cap. Then pierce the seal of the tube with the pin on the top of the cap.

MANUFACTURED BY

See outer carton.

DATE OF REVISION OF THE TEXT

November 2004

Janssen

MINAPHARM
Under Licence of
JANSSEN PHARMACEUTICA
Belgium